Chemotherapy in acute myelogenous leukemia: high dose, higher expectations?
E Berman
JCO Jan 1 1995: 1–4. [PDF]
Is bigger better?
JM Jessup
JCO Jan 1 1995: 5–7. [PDF]
Oligometastases
S Hellman and RR Weichselbaum
JCO Jan 1 1995: 8–10. [PDF]
	Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial
	E Archimbaud, X Thomas, V Leblond, M Michallet, P Fenaux, C Cordonnier, F Dreyfus, X Troussard, J Jaubert, and P Travade
	JCO Jan 1 1995: 11–18. [Abstract] [PDF]
	Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries
	AM Bunt, J Hermans, VT Smit, CJ van de Velde, GJ Fleuren, and JA Bruijn
	JCO Jan 1 1995: 19–25. [Abstract] [PDF]
	Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial
	S Cascinu, L Cordella, E Del Ferro, M Fronzoni, and G Catalano
	JCO Jan 1 1995: 26–32. [Abstract] [PDF]
	Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators
	PC Clahsen, CJ van de Velde, K Welvaart, OJ van Driel, and RJ Sylvester
	JCO Jan 1 1995: 33–41. [Abstract] [PDF]
	Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation
	R Rajan, A Gafni, M Levine, J Hirsh, and M Gent
	JCO Jan 1 1995: 42–46. [Abstract] [PDF]
	Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy
	C Leonard, M Corkill, J Tompkin, B Zhen, D Waitz, L Norton, and J Kinzie
	JCO Jan 1 1995: 47–53. [Abstract] [PDF]
	Pepsinogen C is a new prognostic marker in primary breast cancer
	F Vizoso, LM Sanchez, I Diez-Itza, AM Merino, and C Lopez-Otin
	JCO Jan 1 1995: 54–61. [Abstract] [PDF]
	Cured of breast cancer?
	H Joensuu and S Toikkanen
	JCO Jan 1 1995: 62–69. [Abstract] [PDF]
	Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas
	AG van der Zee, H Hollema, AJ Suurmeijer, M Krans, WJ Sluiter, PH Willemse, JG Aalders, and EG de Vries
	JCO Jan 1 1995: 70–78. [Abstract] [PDF]
	Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trial
	DF Bajorin, CR Nichols, HJ Schmoll, PW Kantoff, C Bokemeyer, GD Demetri, LH Einhorn, and GJ Bosl
	JCO Jan 1 1995: 79–86. [Abstract] [PDF]
	Prognostic significance of early serum tumor marker half-life in metastatic testicular teratoma
	MJ Stevens, AR Norman, DP Dearnaley, and A Horwich
	JCO Jan 1 1995: 87–92. [Abstract] [PDF]
	Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate
	L Harlan, O Brawley, F Pommerenke, P Wali, and B Kramer
	JCO Jan 1 1995: 93–100. [Abstract] [PDF]
	Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years
	BE Johnson, RI Linnoila, JP Williams, DJ Venzon, P Okunieff, GB Anderson, and GE Richardson
	JCO Jan 1 1995: 101–111. [Abstract] [PDF]
	Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs- in-1-day regimen. Childrens Cancer Group
	JL Finlay, JM Boyett, AJ Yates, JH Wisoff, JM Milstein, JR Geyer, SJ Bertolone, P McGuire, JM Cherlow, and M Tefft
	JCO Jan 1 1995: 112–123. [Abstract] [PDF]
	Results of the United Kingdom Children's Cancer Study Group first Wilms' Tumor Study
	J Pritchard, J Imeson, J Barnes, S Cotterill, D Gough, HB Marsden, P Morris- Jones, and D Pearson
	JCO Jan 1 1995: 124–133. [Abstract] [PDF]
	Gonadal function following chemotherapy for Hodgkin's disease: a comparative study of MVPP and a seven-drug hybrid regimen
	ST Clark, JA Radford, D Crowther, R Swindell, and SM Shalet
	JCO Jan 1 1995: 134–139. [Abstract] [PDF]
	Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center
	PW Johnson, AZ Rohatiner, JS Whelan, CG Price, S Love, J Lim, J Matthews, AJ Norton, JA Amess, and TA Lister
	JCO Jan 1 1995: 140–147. [Abstract] [PDF]
	Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood
	R Pettengell, PJ Woll, N Thatcher, TM Dexter, and NG Testa
	JCO Jan 1 1995: 148–156. [Abstract] [PDF]
	Ketoconazole in the management of paraneoplastic Cushing's syndrome secondary to ectopic adrenocorticotropin production
	EW Winquist, J Laskey, M Crump, F Khamsi, and FA Shepherd
	JCO Jan 1 1995: 157–164. [Abstract] [PDF]
	Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem
	AG Freifeld, T Walsh, D Marshall, J Gress, SM Steinberg, J Hathorn, M Rubin, P Jarosinski, V Gill, and RC Young
	JCO Jan 1 1995: 165–176. [Abstract] [PDF]
	Effect of body position on ventricular CSF methotrexate concentration following intralumbar administration
	SM Blaney, DG Poplack, K Godwin, CL McCully, R Murphy, and FM Balis
	JCO Jan 1 1995: 177–179. [Abstract] [PDF]
	Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
	L Gianni, CM Kearns, A Giani, G Capri, L Vigano, A Lacatelli, G Bonadonna, and MJ Egorin
	JCO Jan 1 1995: 180–190. [Abstract] [PDF]
	Clinical and pharmacologic analysis of hyperfractionated daily oral etoposide
	H Minami, Y Ando, S Sakai, and K Shimokata
	JCO Jan 1 1995: 191–199. [Abstract] [PDF]
	Phase I clinical and pharmacokinetic study of oral etoposide phosphate
	C Sessa, M Zucchetti, T Cerny, O Pagani, F Cavalli, M De Fusco, J De Jong, D Gentili, C McDaniel, and C Prins
	JCO Jan 1 1995: 200–209. [Abstract] [PDF]
	Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
	D Abigerges, GG Chabot, JP Armand, P Herait, A Gouyette, and D Gandia
	JCO Jan 1 1995: 210–221. [Abstract] [PDF]
	Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea
	S Wadler, H Haynes, and PH Wiernik
	JCO Jan 1 1995: 222–226. [Abstract] [PDF]
	Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial
	R Whittington, D Neuberg, WJ Tester, AB Benson, 3rd, and DG Haller
	JCO Jan 1 1995: 227–232. [Abstract] [PDF]
	Complications of indwelling venous access devices in cancer patients
	BJ Eastridge and AT Lefor
	JCO Jan 1 1995: 233–238. [Abstract] [PDF]
	Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial
	MA Lew, K Kehoe, J Ritz, KH Antman, L Nadler, LA Kalish, and R Finberg
	JCO Jan 1 1995: 239–250. [Abstract] [PDF]
	Prognostic significance of magnetic resonance imaging in patients with asymptomatic multiple myeloma
	LA Moulopoulos, MA Dimopoulos, TL Smith, DM Weber, KB Delasalle, HI Libshitz, and R Alexanian
	JCO Jan 1 1995: 251–256. [Abstract] [PDF]
	Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome
	TM Kuzel, HH Roenigk, Jr, E Samuelson, JJ Herrmann, A Hurria, AW Rademaker, and ST Rosen
	JCO Jan 1 1995: 257–263. [Abstract] [PDF]
	Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan
	AK Thom, HR Alexander, MP Andrich, WC Barker, SA Rosenberg, and DL Fraker
	JCO Jan 1 1995: 264–273. [Abstract] [PDF]
	Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site
	RJ Motzer, E Rodriguez, VE Reuter, GJ Bosl, M Mazumdar, and RS Chaganti
	JCO Jan 1 1995: 274–282. [Abstract] [PDF]
	Treatment of testicular cancer and the development of secondary malignancies
	C Bokemeyer and HJ Schmoll
	JCO Jan 1 1995: 283–292. [Abstract] [PDF]
The eligibility of women for clinical research trials
WB Patterson and EJ Emanuel
JCO Jan 1 1995: 293–299. [PDF]
The role of the American Society of Clinical Oncology in cancer control worldwide
RR Love, CS Cleeland, and CD Sherman, Jr
JCO Jan 1 1995: 300a. [PDF]
Prognostic factors in bladder cancer after primary M-VAC
L Paz-Ares, J Paul, and S Kaye
JCO Jan 1 1995: 300b–302. [PDF]
Phase II window therapy
RJ Wells
JCO Jan 1 1995: 302–303. [PDF]
Multidrug-resistance modulation in metastatic breast cancer patients
K Mross
JCO Jan 1 1995: 303–304. [PDF]
Life-threatening hyperleukocytosis and pulmonary compromise after priming with recombinant human granulocyte-macrophage colony- stimulating factor in a patient with acute myelomonocytic leukemia
AI Einzig, JP Dutcher, and PH Wiernik
JCO Jan 1 1995: 304–305. [PDF]
Radiation-recall dermatitis in a patient treated with paclitaxel
KA Phillips, M Urch, and JF Bishop
JCO Jan 1 1995: 305. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.